Press Room

Press Release / Oct 08, 2007

Hovione in New Jersey awarded VPP Star status by OSHA

Loures, Portugal, October 8, 2007 – Hovione announces that its Technology Transfer Centre (TTC) has been accepted for Star participation to the Voluntary Protection Program by the Occupational Safety & Health Administration – OSHA. The VPP Star plaque and Flag presentation ceremony will take place next 11th October in East Windsor, New Jersey at 3pm.

At present, only 44 sites in New Jersey have obtained the VPP Star designation. Just to apply, the facilities need to have a minimum of 3 years of unblemished track record. The TTC started operations in 2001 and OSHA accepted our application less than 12 months after it was first submitted. This shows the commitment to worker safety and health that has existed at the TTC since its inception.

Guy Villax, Hovione CEO said: “I am very proud of the achievement of my colleagues. This award takes our TTC to the next level, it is a status that the Team in New Jersey will have to work hard to maintain. Continuing to deserve this is central to building our company culture. Safe operations are the result of good management and dedicated people. This is what gets customers to come back for more. I think it is terrific that, just like all our other sites, the TTC in New Jersey continues the Hovione tradition of collecting awards for doing important things well - well done!”.

Working with industry and labor, the federal Occupational Safety & Health Administration created the Voluntary Protection Program (VPP) in 1980 to recognize and partner with worksites that implement exceptional systems to manage worker safety and health. The management and employees at these sites voluntarily implement comprehensive safety & health management systems - that go far beyond basic compliance with OSHA regulations.

The VPP process emphasizes holding managers accountable for worker safety & health through measurable goals, the continual identification and elimination of hazards and the active involvement of employees in their own protection. The process places significant reliance on the cooperation and trust inherent in a partnership. Sites choosing to apply for VPP recognition show their commitment to effective worker protection by inviting government regulators into their workplace. In return, OSHA removes them from programmed inspections and does not issue citations for violations that are promptly corrected.

About Hovione
Hovione is an international group specializing in the development and compliant production of active pharmaceutical ingredients (APIs), serving exclusively the pharmaceutical industry. With FDA inspected plants in Europe and the Far East and a Technology Transfer Center in New Jersey, Hovione is committed to the highest levels of service and quality. Specializing in complex chemistry, Hovione offers services related to the development and manufacture of either a new chemical entity (NCE) for an exclusive contract manufacturing partner or an existing API for an off-patent product.

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026